Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460551 · ClinicalTrials.gov registry record · Phase 2
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
A Phase 2 study, sponsored by Genmab.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00460551: Clinical Trial Phase 2 study, sponsored by Genmab.
NCT00460551 is a Phase 2 study that was terminated before completion, run by Genmab. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00460551, a Phase 2 study, was terminated before completion, sponsored by Genmab.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.
Primary Outcome
Disease progression was planned to be confirmed using RECIST criteria J Natl Cancer Inst 2000;92:205-16
Interventions
- RADIATION Radiotherapy
- BIOLOGICAL Zalutumumab
- DRUG Induction chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Why NCT00460551 stopped before completion
NCT00460551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Radiotherapy is the first listed.
NCT00460551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00460551 about?
NCT00460551 is a clinical study titled "Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer". The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.
What is the current status of trial NCT00460551?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2007-04. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00460551?
The interventions under investigation include: Radiotherapy (RADIATION), Zalutumumab (BIOLOGICAL), Induction chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00460551?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00460551's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia